Updates are available Correction dated 2024-07-22
Click to view Correction: https://doi.org/10.1038/s41598-024-67936-4
-
Authors
Prasanth, Mani Iyer
Wannigama, Dhammika Leshan
Reiersen, Angela Michelle
Thitilertdecha, Premrutai
Prasansuklab, Anchalee
Tencomnao, Tewin
Brimson, Sirikalaya
Brimson, James Michael
-
Funding
Funding for this research was provided by:
Ratchadapisek Sompote Fund for the Postdoctoral Fellowship
the Ratchadaprisk Sompoch Endowment Fund (2023) Chulalongkorn University (Sys_66_007_3700_001)
- License Information
-
More Information
Article History
Received: 12 March 2024
Accepted: 6 June 2024
First Online: 12 June 2024
Change Date: 22 July 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-024-67936-4
Competing interests
: AMR is listed as an inventor on a patent application related to methods of treating COVID-19 (including Sigma1 agonists and specifically fluvoxamine), which was filed by Washington University in St. Louis. No other author declares any potential conflict of interest or competing financial or non-financial interest in relation to the manuscript. AMR is listed on a patent application that includes the use of σ1R agonists for the treatment of COVID-19. No other authors have any conflicts to declare.
